Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.German biotech company GenPat77 has been awarded a grant to support development of the company's novel immuno-modulator program in inflammatory bowel disease, and for the selection of future biological therapeutics.
Subscribe to our email newsletter
The award is from the German Federal Ministry for Education and Research (BMBF) as part of the BioChancePLUS program which helps small and medium-sized biotech companies to develop and implement biotechnological processes and products.
GenPat77 is developing two types of biological therapeutics, fusion proteins and monoclonal antibodies, targeting CEACAM1. The most advanced, CEACAM1-Fc fusion protein is currently in advanced preclinical studies. These molecules have already shown significant efficacy in models of inflammatory bowel disease.
“We believe that therapies targeting CEACAM1 have potential to address several disorders such as inflammatory bowel disease, other autoimmune diseases and cancer,” noted Dr Nalan Utku, CEO of GenPat77. “This BioChancePlus grant will provide the resources needed to advance this very promising program through to IND filing.”